Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Spitzweg

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Thyroid : Official Journal of the American Thyroid Association|November 22, 2001
Cloning of the mouse sodium iodide symporterL A Pinke, D S Dean, E R Bergert, et al.
Endocrine-Related Cancer|July 14, 2021
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatmentC Spitzweg, P J Nelson, E Wagner, et al.
Kidney International|March 7, 2001
Expression of the sodium iodide symporter in human kidneyC Spitzweg, C M Dutton, M R Castro, et al.
Endocrinology|July 17, 2003
Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cellsC Spitzweg, I V Scholz, E R Bergert, et al.
Gene Therapy|November 13, 2001
In vivo sodium iodide symporter gene therapy of prostate cancerC Spitzweg, A B Dietz, M K O'Connor, et al.
Cancer Research|May 8, 1999
Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell linesC Spitzweg, S Zhang, E R Bergert, et al.
Radiologie (Heidelberg, Germany)|May 7, 2024
[Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology]R Ebner, J Rübenthaler, J Ricke, et al.
Gene Therapy|October 6, 2012
Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirusG K Grünwald, K Klutz, M J Willhauck, et al.
Gene Therapy|October 29, 2004
Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transferI V Scholz, N Cengic, C H Baker, et al.
BMC Cancer|August 10, 2019
Salvage PRRT with <sup>177</sup>Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survivalS Rudisile, A Gosewisch, V Wenter, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Thyroid : Official Journal of the American Thyroid Association|November 22, 2001
Cloning of the mouse sodium iodide symporterL A Pinke, D S Dean, E R Bergert, et al.
Endocrine-Related Cancer|July 14, 2021
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatmentC Spitzweg, P J Nelson, E Wagner, et al.
Kidney International|March 7, 2001
Expression of the sodium iodide symporter in human kidneyC Spitzweg, C M Dutton, M R Castro, et al.
Endocrinology|July 17, 2003
Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cellsC Spitzweg, I V Scholz, E R Bergert, et al.
Gene Therapy|November 13, 2001
In vivo sodium iodide symporter gene therapy of prostate cancerC Spitzweg, A B Dietz, M K O'Connor, et al.
Cancer Research|May 8, 1999
Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell linesC Spitzweg, S Zhang, E R Bergert, et al.
Radiologie (Heidelberg, Germany)|May 7, 2024
[Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology]R Ebner, J Rübenthaler, J Ricke, et al.
Gene Therapy|October 6, 2012
Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirusG K Grünwald, K Klutz, M J Willhauck, et al.
Gene Therapy|October 29, 2004
Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transferI V Scholz, N Cengic, C H Baker, et al.
BMC Cancer|August 10, 2019
Salvage PRRT with <sup>177</sup>Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survivalS Rudisile, A Gosewisch, V Wenter, et al.
Pageof 7